Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $88.95 USD
Change Today +0.06 / 0.07%
Volume 1.1M
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

hospira inc (HSP) Snapshot

Open
$88.82
Previous Close
$88.89
Day High
$88.99
Day Low
$88.82
52 Week High
07/2/15 - $88.99
52 Week Low
10/15/14 - $46.56
Market Cap
15.4B
Average Volume 10 Days
1.4M
EPS TTM
$2.38
Shares Outstanding
172.8M
EX-Date
--
P/E TM
37.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for HOSPIRA INC (HSP)

hospira inc (HSP) Details

Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprise Biosimilars that include Retacrit, an EPO, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent; and Inflectra, a biosimilar infliximab for the treatment of patients with autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease. In addition, it offers medication management products, including infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, the company provides intravenous solutions and nutritional products; and contract manufacturing services, as well as develops proprietary pharmaceutical products, such as Dyloject, a nonsteroidal anti-inflammatory drug analgesic. It serves hospitals and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company has collaborative arrangements with Bioceuticals Arzneimittel AG to license and market Retacrit; and Q Core Medical, Ltd to market and distribute Sapphire, a multi-therapy infusion system. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.

19,000 Employees
Last Reported Date: 02/12/15
Founded in 2003

hospira inc (HSP) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $477.4K
Senior Vice President of Operations
Total Annual Compensation: $464.7K
President of Hospira Medical Devices
Total Annual Compensation: $512.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $550.5K
Compensation as of Fiscal Year 2014.

hospira inc (HSP) Key Developments

The Medicines Company Files Notice of Withdrawal of its Emergency Motion for an Injunction Pending Appeal for Temporary Restraining Order Against Hospira, Inc

The Medicines Company filed a Notice of Withdrawal Without Prejudice with respect to its Emergency Motion for an Injunction Pending Appeal and for a Temporary Restraining Order filed against Hospira Inc. in connection with the parties' pending appeals in The Medicines Company versus Hospira Inc., which involves Hospira's Abbreviated New Drug Applications seeking approval to commercially manufacture, use or sell a generic version of the Company's Angiomax bivalirudin drug product before the expiration of U.S. Patent Nos. 7,582,727 and 7,598,343. The company filed the Notice based on the parties' agreement to maintain the status quo until the earlier of (i) the date of a U.S. Court of Appeals for the Federal Circuit decision concerning the parties' pending appeals in The Medicines Company versus Hospira Inc. (Appeal Nos. 14-1469, 14-1504) or (ii) the close of business on July 7, 2015. The agreement does not prevent the Company from seeking injunctive relief against Hospira at any time.

Hospira Inc. Announces Results from First Real-World Study Show Comparable Effectiveness and Safety of Hospira's Inflectra™ (Infliximab) in Patients with Rheumatic Diseases Switched from Reference Infliximab, Remicade™

Hospira Inc. announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra. The study entitled, 'Clinical experience with infliximab biosimilar' switch from Remicade. Abstract SAT0174,' supports the use of Inflectra, the first biosimilar monoclonal antibody approved in the EU, as a treatment option for people suffering from inflammatory conditions such as rheumatoid arthritis, who are currently receiving stable treatment with reference infliximab. addition, the results of a meta-analysis of 14 randomised controlled trials assessing safety incidences in 1,454 patients were announced at EULAR. The abstract is titled, "Meta-analysis of the safety data between infliximab biosimilar (CT-P13) and innovator infliximab in rheumatoid arthritis and ankylosing spondylitis. Abstract AB0433." This analysis compared the safety profile of Inflectra from clinical trials in RA and AS, with historical safety data from Remicade clinical trials. The results revealed no meaningful differences in safety (infections, serious infections, malignancies/lymphoma, infusion-related reactions) between patients treated with Inflectra and Remicade.

Hospira Inc., Q1 2015 Earnings Call, Apr 28, 2015

Hospira Inc., Q1 2015 Earnings Call, Apr 28, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSP:US $88.95 USD +0.06

HSP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cintas Corp $85.21 USD -0.12
Endo International PLC $82.02 USD +1.13
Mallinckrodt PLC $119.46 USD -0.81
UCB SA €65.58 EUR -1.09
Zimmer Biomet Holdings Inc $108.19 USD -1.02
View Industry Companies
 

Industry Analysis

HSP

Industry Average

Valuation HSP Industry Range
Price/Earnings 45.0x
Price/Sales 3.3x
Price/Book 4.5x
Price/Cash Flow 45.1x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HOSPIRA INC, please visit www.hospira.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.